In PLoS this week: cis loci and 'missing heritability,' predicting miRNA-mRNA interactions based on equilibrium concentrations, Npn-1 and axon-axon interactions, and more.

The agreement enables Qiagen to develop a colorectal cancer blood test based on Epigenomics' mSept9 biomarker and certain DNA methylation analysis technologies.

The grant will support development of inexpensive agriculture diagnostic tests for livestock health in sub-Saharan Africa.

The firm will redeem all of its outstanding 3.25 percent convertible senior subordinated notes due 2024.

If you have a good idea that you want to capitalize on, here are some tips for getting to market.

Researchers believe animal research is important, but some still have "ethical concerns."

Will Watson put physicians "out of work in droves?"

The Archon Genomics X Prize seeks comments on its validation protocol.

In Science this week: translation-independent mRNA migration in E. coli, systems genetics, Eric Lander and Mary-Claire King on genomics, and more.

A researcher looks into why lonely people fall ill more often by looking at their gene expression levels.

The results of the study evaluating the community's ability to identify proteins based on ETD spectra suggest that, while the field has become better at working with this type of mass-spec data, improving researchers' skill and vendors' offerings are still needed.

The firm is currently developing a research-use-only version of the instrument that it expects to launch in 2013 with an FDA-approved version coming sometime after that. It plans to manufacture the RUO device through an outside vendor because most of its parts are off-the-shelf.

Using a new biomarker-discovery workflow under development at BRIMS, researchers hope to find markers that may improve stroke patients' treatment options and shed light onto the biological mechanisms of the disease.

Under the terms of the agreement, Correlogic will sell to AGP patent rights related to the OvaCheck test in Korea, China, Japan, Malaysia, and Singapore in exchange for $80,000, enabling AGP potentially to bring an ovarian cancer diagnostic to market in those countries.

The deal, which is expected to close within weeks, is the latest in a series of purchases of nanoflow LC firms by large mass spec vendors including Thermo Fisher Scientific and AB Sciex.

Pronota will use its proprietary biomarker discovery platform MASStermind and verification platform MASSterclass on the project.

The patent is the first granted to the company for its OvPlex test, which uses a five-protein panel to aid early diagnoses of ovarian cancer in symptomatic women.

Ruedi Aebersold, Anne Ferguson-Smith, Jeannie Lee, Diane Mathis, Dave Anderson, William Thomsen, Jens Holstein, Dave Lemus

Thermo Fisher Scientific, Kinexus

With the offering, Accelrys joins a number of informatics firms that want to exploit the growing NGS market, but the company views the product as a complement to existing offerings, not a rival to them.

The firm will offer a range of customizable bioinformatics and biostatistics solutions to help with biomarker discovery and development, exploratory analysis, mechanistic and functional analysis, traditional and next-generation sequencing data analysis, biostatistics, and data integration.

The R-based tool can purportedly detect copy number changes in short-read data more accurately and faster than existing packages.

Ingenuity and Covance have announced that they will use Ingenuity’s IPA software "to obtain more actionable insights from next-generation sequence data."

Eureka Genomics will provide data-analysis tools while Baylor researchers will provide expertise and clinical resources to understand the causes of colorectal cancer and potentially lead to better prevention, management, and treatment techniques.

Elsevier said this week that all articles on its SciVerse ScienceDirect platform that describe Arabidopsis genes and use AGI codes will now link to the corresponding pages at TAIR to provide readers with access to additional genetic and molecular biology data.